| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2024 | BHC Bausch Health Companies Inc. | Carson Seana60 | EVP, General Counsel | Sell | 6,313 | $9.80 | $61,867.40 | -0.3% | -33.9% | -26.8% | |
| Mar 1, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew48 | Chief Executive Officer | Sell | 384,997 | $13.07 | $5,032,141.79 | -19.4% | +55.3% | +243.7% | |
| Mar 1, 2024 | DVAX Dynavax Technologies Corp | Burgess Justin60 | Chief Accounting Officer | Sell | 20,526 | $12.78 | $262,322.28 | -60.5% | -7.4% | +8.1% | |
| Mar 1, 2024 | PBH Prestige Consumer Healthcare Inc. | Fritz Mary Beth57 | SVP Quality &Regulatory | Sell | 172 | $70.42 | $12,111.76 | -0.5% | -10.5% | +20.8% | |
| Mar 1, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Paolini John F.51 | Chief Medical Officer | Sell | 18,844 | $21.77 | $410,233.88 | -29.6% | -14.6% | -6.7% | |
| Mar 1, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 1,189 | $22.03 | $26,193.67 | -1.0% | -14.6% | -6.7% | |
| Mar 1, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $45.69 | $22,847.34 | -0.3% | -8.8% | -38.5% | |
| Mar 1, 2024 | PRGO Perrigo Co Plc | Willis Robert55 | EVP &CHRO | Buy | 6,371 | $25.90 | $164,977.30 | +14.4% | +4.7% | +10.1% | |
| Mar 1, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Megna Michael R | Chief Accounting Officer | Sell | 14,785 | $21.57 | $318,881.09 | -29.6% | -14.6% | -6.7% | |
| Feb 29, 2024 | PRGO Perrigo Co Plc | Lockwood-Taylor Patrick48 | CEO | Buy | 9,500 | $26.54 | $252,168.00 | +86.4% | +3.6% | +10.4% | |
| Feb 29, 2024 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Operating Officer | Sell | 8,661 | $1.58 | $13,684.38 | -1.2% | -34.8% | +17.1% | |
| Feb 29, 2024 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 546 | $14.17 | $7,736.82 | -0.3% | -12.3% | +9.4% | |
| Feb 29, 2024 | COLL Collegium Pharmaceutical, Inc | Smith Thomas B60 | EVP And Chief Medical Officer | Sell | 995 | $36.76 | $36,580.18 | -1.5% | -9.6% | -20.9% | |
| Feb 29, 2024 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Sell | 7,169 | $1.58 | $11,327.02 | -1.0% | -34.8% | +17.1% | |
| Feb 29, 2024 | PRGO Perrigo Co Plc | Ives Alison57 | EVP &Chief Scientific Officer | Buy | 1,545 | $26.44 | $40,849.80 | +14.2% | +3.6% | +10.4% | |
| Feb 29, 2024 | AKBA Akebia Therapeutics, Inc. | Butler John P.61 | CEO And President | Sell | 46,570 | $1.58 | $73,580.60 | -2.2% | -34.8% | +17.1% | |
| Feb 29, 2024 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 455 | $14.17 | $6,447.35 | -0.5% | -12.3% | +9.4% | |
| Feb 29, 2024 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, Chief Legal Officer | Sell | 5,974 | $1.58 | $9,438.92 | -0.9% | -34.8% | +17.1% | |
| Feb 29, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew48 | Chief Executive Officer | Sell | 577,007 | $12.96 | $7,480,261.05 | -91.8% | +50.2% | +245.8% | |
| Feb 29, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 6,817 | $135.34 | $922,631.73 | -18.5% | +3.2% | -9.0% | |
| Feb 28, 2024 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 75,000 | $134.69 | $10,101,607.50 | -48.0% | +4.3% | -12.7% | |
| Feb 28, 2024 | HIMS Hims & Hers Health, Inc. | Carroll Patrick Harrison52 | Chief Medical Officer | Sell | 20,000 | $13.19 | $263,800.00 | -11.4% | +43.3% | +210.1% | |
| Feb 28, 2024 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 15,000 | $0.08 | $1,199.00 | - | - | - | |
| Feb 28, 2024 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Marketing Officer | Sell | 47,687 | $13.19 | $628,991.53 | -24.6% | +43.3% | +210.1% | |
| Feb 28, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Conway Vikki L | See "remarks" | Sell | 1,366 | $13.12 | $17,916.46 | -31.8% | +28.0% | +24.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.